Does thrombolytic therapy extend home time in patients with ischemic stroke?
Home time is a responsive complementary outcome measure for acute stroke trials that should be adjusted for key baseline covariates.
HT is a responsive measure for use in multinational acute stroke trials. Its inclusion as a complementary outcome is reasonable. We propose treatment effects are adjusted for age, baseline National Institutes of Health Stroke Scale, side of stroke lesion, country of enrollment, and the presence of diabetes.
Mishra et al. (Fri,) studied this question.